The risks of sharing your DNA with online companies aren’t a future concern. They’re here now
By Nila Bala,
Los Angeles Times
| 10. 21. 2024
Turmoil at 23andMe, a company offering popular at-home DNA testing, has upset the industry. Following the resignation of every independent member of the company’s board of directors, its chief executive, Anne Wojcicki, expressed openness to selling the company and its database of around 15 million customers, raising concerns about the misuse of genetic data.
Although Wojcicki has since said she is focused on taking 23andMe private, the data-sharing risks raised by DNA testing and matching companies are already here. A class-action lawsuit filed in August alleges that the operator of GEDmatch.com, a genealogy site that claims to have a database of more than 1 million members, has been sharing users’ information with Facebook. This revelation should alarm us all.
GEDmatch stands apart from companies such as 23andMe. It’s an open, crowdsourced database that anyone can search. Founded in 2010, it emerged as a tool for genealogy enthusiasts to upload DNA results and connect with relatives. It gained notoriety when law enforcement officials announced in 2018 that they had used the service to identify the Golden State...
Related Articles
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Stephanie Pappas, LiveScience | 01.15.2026
Genetic variants believed to cause blindness in nearly everyone who carries them actually lead to vision loss less than 30% of the time, new research finds.
The study challenges the concept of Mendelian diseases, or diseases and disorders attributed to...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...